Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study
Seminars in Thrombosis and Hemostasis · 2026-09 · 52 (06) · 723-731
DOI: 10.1055/a-2779-9176 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 13.01.2026. Verfasst von Valérie Horvais und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, Unité d'Investigation Clinique 17, Nantes, France. Hauptthemen laut MEDLINE: von Willebrand Factor, von Willebrand Diseases, Factor VIII. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Available products for the treatment of von Willebrand disease (VWD) now include a new recombinant von Willebrand factor (rVWF) in addition to plasma-derived concentrates (pdVWF). However, these two therapies have never been compared directly in either preclinical studies or real-world inpatient settings. The Hopscotch Will II study examined the treatment of VWD in hospitals and compared the use of pdVWF and rVWF. Five Rare Bleeding Diseases Centers in Western France retrospectively included patients with VWD over a 48-month period. The data was collected from the BERHLINGO Research Database as well as the French Hospital database, which contains medical information from patient records. Of the 866 patients evaluated in the study, 285 underwent 648 hospitalizations; 126 adult patients (VWD type 3 excluded) were given VWF concentrates during 249 of those hospital stays. rVWF was used in 61% of the cases. The majority of the hospitalizations were motivated by cutaneous-mucosal symptoms in gastroenterology, stomatology, gynecology, and obstetrics. Consumption of rVWF was lower, though the difference in total VWF consumption per stay or per patient per year was not significant: 51 (57)/34 (30) IU/kg/patient/year for pdVWF versus 40 (47)/27 (26) for rVWF (mean [SD]/median [IQR], Wilcoxon rank sum test, p = 0.2025). rVWF was used in similar patient profiles and for identical procedures, but the cost of treatment with rVWF was significantly lower, regardless of whether or not FVIII was added.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nantes Université, CHU Nantes, Unité d'Investigation Clinique 17, Nantes, France.
- Nantes Université, CHU Nantes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Nantes, France.
- CHU Angers, Centre de Traitement des Maladies Hémorragiques Constitutionnelles, Angers, France.
- CHU Brest, Service Hématologie Clinique Hémostase, Brest, France.
- CH Le Mans, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Le Mans, France.
- CHU Rennes, Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Rennes, France.
ORCID-Profile: Valérie Horvais, Julien Denis-Le-Sève, Philippe Beurrier, Marc Fouassier, Antoine Babuty, Nicolas Drillaud, Brigitte Pan-Petesch, Johann Rose, Vincent Cussac, Sophie Bayart, Benoît Guillet, Marc Trossaërt
Zitieren
APA
Horvais, V., Ternisien, C., Denis-Le-Sève, J., Beurrier, P., Fouassier, M., Babuty, A., Drillaud, N., Pan-Petesch, B., Rose, J., Cussac, V., Bayart, S., Guillet, B., & Trossaërt, M. (2026). Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study. Seminars in Thrombosis and Hemostasis, 52(06), 723-731. https://doi.org/10.1055/a-2779-9176
Vancouver
Horvais V, Ternisien C, Denis-Le-Sève J, Beurrier P, Fouassier M, Babuty A, et al. Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study. Seminars in Thrombosis and Hemostasis. 2026;52(06):723-731. doi:10.1055/a-2779-9176
BibTeX
@article{Horvais2026,
author = {Horvais, Valérie and Ternisien, Catherine and Denis-Le-Sève, Julien and Beurrier, Philippe and Fouassier, Marc and Babuty, Antoine and Drillaud, Nicolas and Pan-Petesch, Brigitte and Rose, Johann and Cussac, Vincent and Bayart, Sophie and Guillet, Benoît and Trossaërt, Marc},
title = {Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {06},
pages = {723--731},
doi = {10.1055/a-2779-9176}
}
EUVIMED